Figure 4: Type-I IFNs are dispensable for caspase-5 activation in human monocytes.

(a–d) Quantitative real-time PCR (a,c) and western blot analysis (b,d) of caspase-5 in monocytes treated for different times with IFN-β alone (a,b) or in combination with LPS (c,d). (e) IL-1α, IL-1β and IL-6 release by monocytes treated with LPS alone or in combination with IFN-β for 5 h. (f,g) Monocytes were pre-treated with a neutralizing anti-IFNAR (α-IFNAR) antibody or isotype-matched control antibody (mIgG2a) and then stimulated with IFN-β alone, LPS alone, or IFN-β and LPS together for 5 h. (f) Caspase-5 processing was assessed by western blot (left). Densitometry analysis of caspase-5 p20 was also shown (right). n.s., non significant. (g) Cytokine release was assessed by ELISA. Blots are representative of two or more independent experiments. Graphs show the mean±s.d. of triplicate wells and are representative of three independent experiments.